Crinetics enters into merger agreement with Vertex Pharmaceuticals

Crinetics Pharmaceuticals, Inc.

Merger agreement signed July 6, 2026; Crinetics to become wholly owned subsidiary of Vertex.
Non-compete agreements with CEO Scott Struthers, CFO Tobin Schilke, CSO Stephen Betz, CCO Isabel Kalofonos.
Cash payments at closing: Schilke $140,000, Betz $30,000, Kalofonos $30,000.
No financial terms (price, premium) disclosed in the filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.